CSF2 and melanoma: T-VEC, a genetically modified herpes simplex virus encoding granulocyte-macrophage colony-stimulating factor (GM-CSF), has demonstrated durable responses in melanoma and is now being tested in HNSCC, particularly in combination with ICIs [124].